Matrix metalloproteinase-20 (MMP-20) (MMP-20)

Matrix metalloproteinase-20 (MMP-20), also known as enamelysin, is a zinc-dependent endopeptidase primarily expressed by ameloblasts during the secretory and early maturation stages of tooth enamel formation [1]. Its fundamental biological role involves the precise cleavage of enamel matrix proteins, such as amelogenin, enamelin, and ameloblastin, which is a critical step for the proper growth and organization of hydroxyapatite crystals [2]. Mutations in the MMP20 gene are directly linked to autosomal recessive hypomaturation amelogenesis imperfecta, a condition where the enamel fails to harden properly, leading to brittle and discolored teeth [3]. Beyond its specialized role in dental development, MMP-20 has been identified in various non-dental tissues and is often upregulated in certain malignancies, such as oral squamous cell carcinoma and some brain tumors, where it may facilitate cell invasion and migration [4]. While there are no drugs currently approved that specifically target MMP-20, it is sensitive to broad-spectrum MMP inhibitors like marimastat and batimastat, which act by chelating the essential zinc ion in the enzyme's active site [5]. The therapeutic challenge in targeting MMP-20 lies in achieving selectivity to avoid the musculoskeletal side effects associated with the inhibition of other MMP family members [6]. Additionally, MMP-20 exhibits some gelatinolytic activity in vitro, allowing it to be monitored via gelatin zymography alongside other gelatinases like MMP-2 and MMP-9 [7]. Research into MMP-20 inhibitors is primarily focused on understanding its role in cancer progression and developing potential treatments for enamel-related disorders [8].

Other names

EnamelysinMMP20Matrix metallopeptidase 20

Competitive inhibition of the zinc-dependent catalytic domain, preventing the proteolytic processing of enamel matrix proteins and other extracellular substrates.